.Pharmacolibrary.Drugs.ATC.L.L01EJ02 .Pharmacolibrary.Drugs.ATC.L.L01EJ02| name: | Fedratinib |
| ATC code: | L01EJ02 | route: | oral |
| n-compartments | 2 |
Fedratinib is an oral selective Janus kinase 2 (JAK2) inhibitor indicated for the treatment of adult patients with intermediate-2 or high-risk primary or secondary (post–polycythemia vera or post–essential thrombocythemia) myelofibrosis. It is currently approved by regulatory agencies such as the FDA.
Pharmacokinetic parameters in adult patients with myelofibrosis after repeated oral administration of 400 mg once daily.
Ogasawara, K, et al., & Li, Y (2019). Population pharmacokinetics of fedratinib in patients with myelofibrosis, polycythemia vera, and essential thrombocythemia. Cancer chemotherapy and pharmacology 84(4) 891–898. DOI:10.1007/s00280-019-03929-9 PUBMED:https://pubmed.ncbi.nlm.nih.gov/31444617
Chen, Y, et al., & Krishna, G (2022). Effect of fluconazole on the pharmacokinetics of a single dose of fedratinib in healthy adults. Cancer chemotherapy and pharmacology 90(4) 325–334. DOI:10.1007/s00280-022-04464-w PUBMED:https://pubmed.ncbi.nlm.nih.gov/36001108
Chen, Y, et al., & Ogasawara, K (2025). Exposure-response relationship of fedratinib in patients with intermediate-2 or high-risk myelofibrosis. British journal of clinical pharmacology None –. DOI:10.1002/bcp.70118 PUBMED:https://pubmed.ncbi.nlm.nih.gov/40485284